GMP PCL AOD-9604 5mg

AOD-9604 is a synthetic peptide derived from a modified fragment of human growth hormone (hGH), specifically encompassing amino acid residues 177–191, with an added N-terminal tyrosine to enhance structural stability. The compound has been evaluated in multiple preclinical models for its role in modulating adipose tissue and lipid metabolism without mimicking the full spectrum of hGH activity (Heffernan et al. 2001).

In obese mice, chronic administration of AOD-9604 was shown to significantly increase β3- adrenergic receptor (β3-AR) mRNA expression in both white and brown adipose tissue. This upregulation correlated with reductions in adipose tissue mass. These effects were not reproduced in β3-AR knockout mice, suggesting that the β3-AR plays a key role in the compound’s chronic metabolic effects (Heffernan et al. 2001). Importantly, AOD-9604 does not act via direct binding to β3-AR or hGH receptors, indicating an indirect mechanism of action (Heffernan et al. 2001).

The compound’s safety and pharmacological profile have been comprehensively assessed in rodent models.In preclinical trials, including those involving ovariectomized (OVX) rat models, both low- and high-dose AOD-9604 regimens showed no significant toxicity. Importantly, treatment did not negatively impact markers such as bone mineral density (BMD) or body weight in a manner inconsistent with healthy controls (Fawcett 2010). As AOD-9604 does not interact with the growth hormone receptor, it was not shown to stimulate IGF-1 production and showed no proliferative effects on growth-related endpoints (Fawcett 2010).